




# SCHIZOPHRENIA RESEARCH: COGNITION

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

---

- **Description** p.1
- **Abstracting and Indexing** p.1
- **Editorial Board** p.1
- **Guide for Authors** p.3



ISSN: 2215-0013

### DESCRIPTION

---

*Schizophrenia Research: Cognition* is an international, peer-reviewed open access journal publishing articles on cognition in schizophrenia, broadly defined. The journal publishes original articles, concise research reports, brief reports, letters to the editor, and review papers. Submissions on all aspects of cognition in schizophrenia will be welcome, including clinical neuropsychology, neurocognition, social cognition, functional capacity, cognitive, affective, and social neuroscience, and aspects of everyday outcome as related to cognition. Articles that compare the impact of cognition and other influences on outcome in schizophrenia will also be published. Articles on descriptive characteristics, genetic influences, pharmacological and nonpharmacological treatments, and neuroimaging correlates of these aspects of cognition are welcomed. The journal will also consider submissions aimed at cognition in conditions related to schizophrenia and will also consider articles on cognitive functioning as a marker of vulnerability in various potentially at-risk populations. The journal is online-only and articles will be rapidly available after their acceptance.

### ABSTRACTING AND INDEXING

---

PubMed Central  
Scopus  
Directory of Open Access Journals (DOAJ)

### EDITORIAL BOARD

---

#### **Editor-in-Chief**

**Philip D. Harvey**, Florida, United States

#### **Editorial Board**

**Amelie M. Achim**, Canada  
**André Aleman**, Netherlands  
**Christopher R. Bowie**, Ontario, Canada  
**Benjamin Buck**, Washington, United States  
**Katherine Burdick**  
**Katherine Burdick**  
**Roberto Cavallaro**, Italy  
**Anthony David**, United Kingdom  
**Michael Davidson**, Israel  
**Anne-Katrin Fett**, United Kingdom

**Michael F. Green**, California, United States  
**William Horan**, California, United States  
**Richard S.E. Keefe**, North Carolina, United States  
**Matthew M. Kurtz**, Connecticut, United States  
**Anil Malhotra**, New York, United States  
**Susan R. McGurk**, Massachusetts, United States  
**David Penn**, North Carolina, United States  
**Amy Pinkham**, Texas, United States  
**John D. Ragland**, California, United States  
**Volker Roder**, Switzerland  
**Susan Rossell**  
**George Strauss**, Georgia, United States  
**Tomiki Sumiyoshi**, Japan  
**Jagadisha Thirthalli**, India  
**Eva Velthorst**  
**Eva Velthorst**  
**Eduard Vieta**, Spain  
**Sophia Vinogradov**, California, United States  
**Mark Weiser**, Israel  
**Til Wykes**, United Kingdom

## GUIDE FOR AUTHORS

---

### Instructions for Authors

*Schizophrenia Research: Cognition* is an international, peer-reviewed open access journal publishing articles on cognition in schizophrenia, broadly defined. The journal publishes original articles, concise research reports, brief reports, letters to the editor, and review papers. Submissions on all aspects of cognition in schizophrenia will be welcome, including clinical neuropsychology, neurocognition, social cognition, functional capacity, cognitive, affective, and social neuroscience, and aspects of everyday outcome as related to cognition. Articles that compare the impact of cognition and other influences on outcome in schizophrenia will also be published. Articles on descriptive characteristics, genetic influences, pharmacological and nonpharmacological treatments, and neuroimaging correlates of these aspects of cognition are welcomed. The journal will also consider submissions aimed at cognition in conditions related to schizophrenia and will also consider articles on cognitive functioning as a marker of vulnerability in various potentially at-risk populations. The journal is online-only and articles will be rapidly available after their acceptance. All articles will be peer reviewed and if accepted for publication in the Journal, authors will be notified of this decision and at the same time be required to pay an Article Processing Fee of \$2000 (full-length articles) and \$750 (concise and brief reports). Reviews and Letters will be published at no charge as will papers submitted by authors from Research 4 Life countries.

There will be a 75% discount on the Article Processing Fee for all full-length manuscripts submitted to *Schizophrenia Research: Cognition* by December 31, 2014. In turn, the Article Processing fee for 2014 will be \$500 for full-length articles and \$250 for short reports. Following payment of this fee articles will be made universally available at no further charge through ScienceDirect (<http://www.sciencedirect.com/>) and through the Journal's own website, <http://www.SchizResCognition.com>

### Uniform Requirements

These guidelines generally follow the 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals', published by the International Committee of Medical Journal Editors (ICMJE). The complete document appears at <http://www.icmje.org>.

### Article Information

**Research Papers:**Structure: Abstract, Introduction, Methods, Results, Discussion, and References  
**Abstract:** Limited to 250 words, semi-structured (no titles or references)  
**Total Word Limit:** 3,000 words  
**Checklist:** <http://www.consort-statement.org>  
**Short Communications:**Structure: One body of text with no sub-titles  
**Abstract:** 250 words or none  
**Total Word Limit:** 1,500 words  
**Review Articles:**Structure: Reviews should provide clear introducing and concluding sections. Subtitles are at the author's discretion.  
**Abstract:** Limited to 250 words, semi-structured  
**Total Word Limit:** 3,000 words

### BEFORE YOU BEGIN

*Schizophrenia Research: Cognition* adheres to the ICMJE definition of authorship and authors are requested to review this at: [http://www.icmje.org/ethical\\_1author.html](http://www.icmje.org/ethical_1author.html). Each author must have a specific role in the manuscript. Overall management/supervision of a laboratory alone or a position of chairmanship alone does not constitute an authorship role.

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. For more information on the types of peer review, please visit: [elsevier.com/reviewers/peer-review](http://elsevier.com/reviewers/peer-review).

### Authorship

All authors should have made substantial contributions to all of the following:

- (1) The conception and design of the study, or acquisition of data, or analysis and interpretation of data.
- (2) Drafting the article or revising it critically for important intellectual content.
- (3) Final approval of the version to be submitted.

### Declarations

When submitting a paper authors must declare the following aspects:

(1) **Conflicts of Interest:** At the end of the text, under a subheading 'Conflict of interest statement', all authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

(2) **Ethical Approval** (if required): Work on human beings that is submitted to *Schizophrenia Research: Cognition* should comply with the principles laid down in the Declaration of Helsinki (*Recommendations guiding physicians in biomedical research involving human subjects*. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989). The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed and that subjects gave informed consent to the work. Studies involving experiments with animals must state that their care was in accordance with institution guidelines. Patients and volunteers names, initials, and hospital numbers should not be used.

(3) **Funding Sources:** All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

(4) **Acknowledgements:** All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

### **Submission declaration**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

### **Preprints**

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

### **Author contributions**

For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. [More details and an example](#)

### **Randomized Controlled Trials**

All randomized controlled trials submitted for publication in *Schizophrenia Research: Cognition* should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at <http://www.consort-statement.org> for more information.

*Schizophrenia Research: Cognition* has adopted the proposal from the ICMJE which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number (ISRCTN) should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can be found at <http://www.icmje.org>.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see [more information](#) on this). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

*Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Open access**

This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

*Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

*Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 2100**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

*Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

*Submit your article*

Please submit your article via <https://www.evis.com/profile/api/navigate/SCOG>.

## **PREPARATION**

## Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

## Title

Your title page, numbered as 1, should give the title in capital letters (not exceeding 100 letters), a running title (not exceeding 50 letters) and the authors names (as they are to appear), affiliations and complete addresses, including postal (zip) codes. The author and address to whom correspondence should be sent must be clearly indicated. Please supply telephone number, postal address, and e-mail addresses for the corresponding author.

## Highlights

Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

## Abstract

Our system requires that an abstract be provided to the system for each article. For articles which do not require an abstract, please simply N/A when prompted during the submission process.

## Keywords

A list of three to six keywords should be supplied; full instructions are provided when submitting the article online.

## Units and Abbreviations

Système Internationale (SI) units should be used, with the traditional equivalent in parentheses where appropriate. Conventions for abbreviations should be those detailed in: Baron DN, ed. *Units, Symbols, and Abbreviations: A Guide for Biological and Medical Editors and Authors*. 5th edition. London: Royal Society of Medicine Services, 1994.

## Figures

Figures of good quality (minimum 92 DPI) should be uploaded separately from the text. Permission to reproduce illustrations should always be obtained before submission and details included with the captions.

## Tables

Tables should be uploaded separately from the main text, bear a short descriptive title, and be numbered in Arabic numbers. Tables should be cited in the text.

## References

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use

reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software.](#)

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/schizophrenia-research-cognition>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### *Reference style*

Manuscripts should use the Harvard style for references. Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### **Web references**

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

**Text:** All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication; 2. *Two authors:* both authors' names and the year of publication; 3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

*Examples:* "as demonstrated (Allan, 1996a, 1996b, 1999; Allan and Jones, 1995). Kramer et al. (2000) have recently shown ...."

**List:** References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters "a", "b", "c", etc., placed after the year of publication.

**Journal References:** All authors should be included when there are six or fewer. When seven or more authors are present, the first three should be recorded followed by et al. This should be followed by the year, title of article, name of journal abbreviated according to Index Medicus (see <http://www.nih.nlm.gov>), volume, issue (if recorded), and first and last pages. For example:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2000. The art of writing a scientific article. *J. Sci. Commun.* 163 (2) 51-59.

### **Reference to a book:**

Strunk Jr, W., White, E.B., 1979. *The Elements of Style*, third ed. Macmillan, New York.

### **Reference to a chapter in an edited book:**

Mettam, G.R., Adams, L.B., 1999. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281-304.

### **Reference to datasets:**

Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. *Mendeley Data*, v1. <http://dx.doi.org/10.17632/xwj98nb39r.1>. Journal names should be abbreviated according to the List of serial title word abbreviations: <http://www.issn.org/lstwa.html>

### **Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

#### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

#### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

#### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **Submission Preparation Checklist**

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor). The submission file is in Microsoft Word, OpenOffice, RTF, or WordPerfect document file format. Where available, URLs and access dates for the references have been provided. ALL illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.

- The text is single-spaced
  - uses a 12-point font
  - employs italics, rather than underlining (except with URL addresses)
- The text adheres to the stylistic and bibliographic requirements outlined in these Author Guidelines. If submitting to a peer-reviewed section of the journal, the instructions in Ensuring a Blind Review have been followed. Please submit your manuscript and illustrations as outlined herein to: <https://www.eviser.com/profile/api/navigate/SCOG>

### **AFTER ACCEPTANCE**

Visit <https://www.elsevier.com/authors> for the facility to track accepted articles and set email alerts to inform you of when an article's status has changed. The website also provides detailed artwork guidelines, copyright information, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those related to proofs, are provided after registration of an article for publication.

## Proofs

One set of page proofs in PDF format will be sent by e-mail to the corresponding author, which they are requested to correct and return within 48 hours. Elsevier now sends PDF proofs that can be annotated; for this you will need to download Adobe Reader version 7 available free from <http://get.adobe.com/reader>. Instructions on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe website: <http://www.adobe.com/products/reader/tech-specs.html>.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post.

Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

## Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

## Offprints

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

## Offprints

The corresponding author will be notified and receive a link to the published version of the open access article on [ScienceDirect](https://www.sciencedirect.com). This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Author Services](#).

## AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>